Can I Take Resveratrol with Vyvanse?

What Vyvanse Is and How It Is Cleared

Vyvanse (lisdexamfetamine dimesylate) is a Schedule II central nervous system stimulant and prodrug medication approved by the FDA to treat ADHD in children age 6 and up, as well as moderate-to-severe binge eating disorder in adults. Once taken, lisdexamfetamine is broken down by peptide hydrolase enzymes found in red blood cells to produce active d-amphetamine; because this activation occurs in the bloodstream rather than in the liver, it avoids interactions with hepatic enzyme inhibitors.

Once d-amphetamine is circulating, the body clears it through several routes: monoamine oxidase (MAO) inactivates a portion, CYP2D6 produces 4-hydroxyamphetamine, and CYP3A4 contributes to N-demethylation, particularly at higher amphetamine concentrations. Urinary elimination of unchanged amphetamine is pH-dependent. The current FDA prescribing information identifies MAO inhibitors as the most serious contraindicated interaction and notes CYP2D6 involvement in amphetamine metabolism. Verify the exact current label language directly, since prescribing information is updated periodically and dated citations can lag behind the live label.

What Resveratrol Is

Resveratrol (3,5,4-trihydroxystilbene) is a stilbenoid polyphenol found in grapes, blueberries, peanuts, and Japanese knotweed root. Supplement products typically range from 50 mg to 1,000 mg per capsule; some longevity-focused regimens use doses of 500 mg to 2,000 mg per day, far above what a person would consume from food or wine.

In laboratory and small human pharmacokinetic studies, resveratrol has been reported to inhibit CYP3A4 at higher doses (in the range of roughly 500 to 1,000 mg per day and above) and to have a weaker, more dose-dependent effect on CYP2D6. These enzyme-inhibition findings come from published pharmacokinetic literature on resveratrol generally, not from any study involving lisdexamfetamine specifically. The exact papers and inhibition magnitudes should be verified against the primary literature before being cited as precise figures; this article deliberately avoids repeating specific percentage estimates that cannot be confirmed from a verified primary source.

Is There a Documented Interaction Between Resveratrol and Vyvanse?

No. A direct search for clinical or pharmacokinetic studies pairing lisdexamfetamine with resveratrol returned no matching published research. The assessment below is built entirely from mechanistic reasoning: resveratrol inhibits enzymes that participate in amphetamine clearance, so it is biologically plausible that high-dose resveratrol could modestly slow amphetamine metabolism. That plausibility is not the same as a demonstrated clinical effect, and no controlled study has measured Vyvanse plasma levels, heart rate, or blood pressure in people taking both substances together.

Evidence-Status Interaction Assessment

Pharmacodynamic Considerations Beyond Enzyme Inhibition

Vyvanse raises heart rate and blood pressure through its sympathomimetic mechanism, an effect well documented in its clinical trial program and reflected in the FDA label's cardiovascular warnings. Resveratrol has been studied at lower doses (around 150 mg/day) for mild vasodilatory and lipid-related cardiovascular effects in small trials, though findings across studies are inconsistent. Whether these opposing tendencies cancel out, add together in an unpredictable way, or have no measurable combined effect has not been studied and should not be assumed either way.

Resveratrol has also shown MAO-inhibiting activity in laboratory models, but at concentrations well above what oral supplementation typically produces in human plasma. This is a mechanistic flag, not a documented clinical risk at standard supplement doses. It does mean that resveratrol should not be treated as pharmacologically inert simply because it is sold over the counter, and it should not be combined with Vyvanse during or within two weeks of using a pharmaceutical MAO inhibitor, consistent with Vyvanse's existing contraindication.

Resveratrol also binds estrogen receptors with low affinity and may have weak estrogenic activity at higher supplement doses. This is a separate consideration from the CYP question and is most relevant for women managing hormonal contraception or other estrogen-sensitive conditions alongside Vyvanse.

Who Should Be More Cautious

• People taking high-dose resveratrol (roughly 500 mg/day or more). This is the dose range where CYP3A4 inhibition becomes more clinically plausible based on general resveratrol pharmacokinetic data.
• Known or suspected CYP2D6 poor metabolizers. This group already relies more on alternate clearance pathways for amphetamine and may be more sensitive to added CYP3A4 inhibition.
• Older adults. Hepatic CYP3A4 activity tends to decline with age, which could compound any inhibitory effect from resveratrol.
• People with cardiovascular disease or poorly controlled blood pressure. Any additive uncertainty around heart rate or blood pressure warrants closer monitoring in this group regardless of mechanism.
• Enhanced-bioavailability resveratrol formulations. Standard trans-resveratrol has low oral bioavailability due to rapid gut and liver conjugation. Piperine-enhanced or liposomal formulations can raise plasma concentrations several-fold at the same labeled milligram dose, which means a lower labeled dose of an enhanced product could behave pharmacokinetically like a much higher dose of a standard capsule. This is a meaningful detail to share with a prescriber, since "250 mg" does not mean the same thing across products.

People taking dietary amounts of resveratrol from food (grapes, wine, berries) are exposed to far lower amounts than any dose studied for CYP inhibition and are not a population of concern here.

A Practical Way to Approach This With a Prescriber

1. Before starting resveratrol, tell the clinician managing Vyvanse which product you are considering, including the milligram dose and whether it is standard, piperine-enhanced, or liposomal.
2. If available, share prior pharmacogenomic testing results (CYP2D6 metabolizer status), since this changes the risk calculation.
3. If you start resveratrol, begin at the lowest available dose and avoid taking it at the same time of day as Vyvanse initially, so any new symptom is easier to attribute.
4. Track resting heart rate, blood pressure, sleep onset, and anxiety symptoms for the first two to four weeks. A sustained rise in heart rate or blood pressure, new or worsened insomnia, or new anxiety symptoms should be reported to the prescriber rather than managed on your own.
5. Seek urgent care for chest pain, a pounding or irregular heartbeat with dizziness, severe headache, or signs of a hypertensive crisis. These are not expected effects of either substance alone at typical doses, and they warrant immediate evaluation regardless of suspected cause.

Vyvanse's Established Interactions, for Context

Placed next to established interactions, resveratrol sits well below the threshold of an automatic contraindication. Fluoxetine and paroxetine are strong, well-documented CYP2D6 inhibitors with measured effects on amphetamine levels; resveratrol's CYP2D6 effect is weaker and less consistently demonstrated across studies.

Special Populations

Women of reproductive age. Resveratrol's weak estrogenic activity and CYP3A4 inhibition are both relevant if combined with a CYP3A4-metabolized hormonal contraceptive. The clinical significance at typical supplement doses appears low but has not been directly studied; discuss this combination with an OB-GYN or prescribing clinician.

Adolescents. Vyvanse is approved down to age 6, but resveratrol has no established safety data in children or adolescents and carries a weak estrogenic signal that is a reasonable concern during puberty. It is not advisable to add resveratrol to an adolescent's regimen without specific pediatric guidance.

Older adults. Reduced CYP3A4 activity with age may increase sensitivity to any resveratrol-related enzyme inhibition. This is a reason for more conservative dosing and closer monitoring, not a reason for automatic avoidance.

What Is Established, What Is Plausible, and What Is Not Known

Established: Vyvanse's metabolic pathways and its documented contraindication with MAO inhibitors, from the FDA label. Resveratrol's general CYP3A4 and (weaker) CYP2D6 inhibitory activity, from the broader pharmacokinetic literature on resveratrol.

Plausible but unproven: that resveratrol, particularly at doses above roughly 500 mg/day or in enhanced-bioavailability forms, could modestly raise plasma amphetamine levels and intensify or prolong stimulant effects in some patients, especially CYP2D6 poor metabolizers or older adults.

Not established: any measured change in Vyvanse pharmacokinetics, heart rate, blood pressure, or side effect frequency when resveratrol is added, since no study has tested this specific combination. Readers should not treat any specific numeric estimate of interaction magnitude as confirmed unless it comes from a verified primary source reviewed by a clinician.